At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.
In Brief
An observational study evaluating Diagnosis, Molecular and Karyotype, and 1 other intervention for Promyelocytic Leukemia, Acute. Completed, enrolled 360 participants across 1 site.
Detailed Summary
Retrospective, observational study, comparing treatments of acute promyelocytic leukemia in different centers in México. There is no sufficient information about acute promyelocytic leukemia in America Latina, particularly in Mexico. For these reason the investigators started a study adding all promyelocityc patients from the main Hospital in Mexico in order to put together a group of patient and analyze the response, overall survival and what are the characteristics of the population. The investigators included 5 Hospital in Mexico City and states as Monterrey, Guadalajara, San Luis Potosi, Puebla, Veracruz, Yucatán, Oaxaca, Guanajuato, Estado de México. Even do, the investigators didn´t have arsenic trioxide they are treating patients with standard chemotherapy. These paper will help to show the authorities that the cost of treating patient with standard chemotherapy is much more higher than ATO-ATRA. The investigators are now doing a cost benefit analysis so the investigators, can soon have ATO treatment as standard of care in Mexico for the treatment of acute promyelocytic leukemia.
Study Details
Timeline
Interventions
Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
To realize the need of having more center we the technology to perform all of these tests